About
Copy Link
Titles
Research Assistant 2 HSS
Biography
Stephen came to the clinic with a long-held interest in anxiety disorders and OCD. He coordinates studies, conducts clinical assessment and education, facilitates psychedelic study sessions, and trains staff.
Last Updated on January 21, 2025.
Education & Training
- MPH
- University of Connecticut
- BA
- Central Connecticut State University, Psychology
Research
Copy Link
Overview
Medical Research Interests
Anxiety Disorders; Behavior Therapy; Emotions; Health Education
- View Lab Website
Yale OCD Research Clinic
Research at a Glance
Yale Co-Authors
Frequent collaborators of Stephen Kichuk's published research.
Publications Timeline
A big-picture view of Stephen Kichuk's research output by year.
Christopher Pittenger, MD, PhD
Terence Ching, PhD
Benjamin Kelmendi, MD
Brian Zaboski, PhD
Michael Bloch, MD, MS
Rachael Grazioplene
Former YSM
19Publications
529Citations
Publications
2026
Classifying Obsessive-Compulsive Disorder from Resting-State EEG Using Convolutional Neural Networks: A Pilot Study
Zaboski B, Fineberg S, Skosnik P, Kichuk S, Fitzpatrick M, Pittenger C. Classifying Obsessive-Compulsive Disorder from Resting-State EEG Using Convolutional Neural Networks: A Pilot Study. Computational Psychiatry 2026, 10: 1-17. PMID: 41585367, PMCID: PMC12829452, DOI: 10.5334/cpsy.149.Peer-Reviewed Original ResearchCitations
2025
Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis
Ching T, Stahnke B, Shnayder S, Agin-Liebes G, Adams T, Amoroso L, Baiz O, Belser A, Bohner C, Burke M, D’Amico E, DePalmer G, Eilbott J, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Purohit P, Schaer H, Sierra Y, Witherow C, Pittenger C, Kelmendi B. Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis. Frontiers In Psychiatry 2025, 16: 1726818. PMID: 41450831, PMCID: PMC12728583, DOI: 10.3389/fpsyt.2025.1726818.Peer-Reviewed Original ResearchThis study investigates the effects of single-dose psilocybin on treatment-resistant obsessive-compulsive disorder, finding symptom reductions linked to insights, emotional shifts, and improved psychological flexibility.Moderators and Mediators of the Relationship Between Social Support and Readiness To Change in OCD
King K, Kichuk S, Pittenger C, Zaboski B. Moderators and Mediators of the Relationship Between Social Support and Readiness To Change in OCD. Journal Of Contemporary Psychotherapy 2025, 56: 91-98. DOI: 10.1007/s10879-025-09692-8.Peer-Reviewed Original ResearchCitations#OCD: A Content Analysis of Obsessive-Compulsive Disorder Stereotype Amplification and Misinformation on TikTok
Fitzpatrick M, Moore A, Kichuk S, Pittenger C, Zaboski B. #OCD: A Content Analysis of Obsessive-Compulsive Disorder Stereotype Amplification and Misinformation on TikTok. Cyberpsychology Behavior And Social Networking 2025, 28: 607-615. PMID: 40842159, DOI: 10.1177/21522715251370135.Peer-Reviewed Original ResearchCitationsAltmetric
2024
Suicidal Obsessions or Suicidal Ideation? A Case Report and Practical Guide for Differential Assessment
Mattera E, Ching T, Zaboski B, Kichuk S. Suicidal Obsessions or Suicidal Ideation? A Case Report and Practical Guide for Differential Assessment. Cognitive And Behavioral Practice 2024, 31: 259-271. DOI: 10.1016/j.cbpra.2022.09.002.Peer-Reviewed Original ResearchCitationsAltmetricMechanisms of therapeutic change after psychedelic treatment in OCD
Maloney G, Ching T, Kichuk S, Pittenger C, Kelmendi B. Mechanisms of therapeutic change after psychedelic treatment in OCD. Psychiatry Research 2024, 336: 115907. PMID: 38615521, PMCID: PMC11190873, DOI: 10.1016/j.psychres.2024.115907.Peer-Reviewed Original ResearchCitationsAltmetricCorrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Ching T, Amoroso L, Bohner C, D'Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B. Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Frontiers In Psychiatry 2024, 15: 1372373. PMID: 38435972, PMCID: PMC10905264, DOI: 10.3389/fpsyt.2024.1372373.Commentaries, Editorials and LettersSafety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings
Ching T, Amoroso L, Bohner C, D’Amico E, Eilbott J, Entezar T, Fitzpatrick M, Fram G, Grazioplene R, Hokanson J, Jankovsky A, Kichuk S, Martins B, Patel P, Schaer H, Shnayder S, Witherow C, Pittenger C, Kelmendi B. Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings. Frontiers In Psychiatry 2024, 14: 1278823. PMID: 38264632, PMCID: PMC10803438, DOI: 10.3389/fpsyt.2023.1278823.Peer-Reviewed Original ResearchCitationsAltmetric
2023
Neurofeedback for obsessive compulsive disorder: A randomized, double-blind trial
Rance M, Zhao Z, Zaboski B, Kichuk S, Romaker E, Koller W, Walsh C, Harris-Starling C, Wasylink S, Adams T, Gruner P, Pittenger C, Hampson M. Neurofeedback for obsessive compulsive disorder: A randomized, double-blind trial. Psychiatry Research 2023, 328: 115458. PMID: 37722238, PMCID: PMC10695074, DOI: 10.1016/j.psychres.2023.115458.Peer-Reviewed Original ResearchCitationsAltmetricSafety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial
Ching T, Grazioplene R, Bohner C, Kichuk S, DePalmer G, D’Amico E, Eilbott J, Jankovsky A, Burke M, Hokanson J, Martins B, Witherow C, Patel P, Amoroso L, Schaer H, Pittenger C, Kelmendi B. Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial. Frontiers In Psychiatry 2023, 14: 1178529. PMID: 37181888, PMCID: PMC10166878, DOI: 10.3389/fpsyt.2023.1178529.Peer-Reviewed Original ResearchCitationsAltmetric
News
Copy Link
Get In Touch
Copy Link
Contacts
Academic Office Number